Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:31:48.344Z.
Calculation as of: 2026-10-06T16:31:48.344Z.
Quote observation: 2026-10-06T16:30:26.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 719625f658538d7511a1815ebd8f3969041d2dee7d9c9a78aa46ea1e1d2f6eab
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$308.38M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$299.52M
EV/EBITDA Ratio
N/A
TTM Avg
22.81x
3Y Avg
22.81x
5Y Avg
22.81x
Market Cap
$350.90M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CapsoVision, Inc. (CV) | $324.01M | N/A | N/A | N/A | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $324.71M | N/A | N/A | N/A | N/A |
| Avita Medical Inc. (RCEL)vs › | $320.74M | N/A | N/A | N/A | N/A |
| C4 Therapeutics, Inc. (CCCC)vs › | $317.88M | N/A | N/A | N/A | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $326.11M | N/A | N/A | N/A | N/A |
| Agenus Inc. (AGEN)vs › | $333.02M | 8.67x | 20.16x | 20.16x | 12.62x |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $308.38M | N/A | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $299.52M | N/A | 22.81x | 22.81x | 22.81x |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $350.90M | N/A | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $295.61M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
